Decolonization therapy in infection control

Current Opinion in Infectious Diseases

Volumn 23, Issue 4, 2010, Pages 340-345

  Hebert, Courtney ^a   Robicsek, Ari ^a,b,c,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c Department of Infection Control ^*  (United States)

^d Center for Clinical Research Informatics   (United States)

Author keywords

decolonization; infection control; methicillin resistant Staphylococcus aureus

Indexed keywords

CHLORHEXIDINE; ANTIINFECTIVE AGENT; PSEUDOMONIC ACID; TOPICAL ANTIINFECTIVE AGENT;

BLOODSTREAM INFECTION; DIGESTIVE SYSTEM; DISINFECTION; HEART SURGERY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; DRUG THERAPY; HETEROZYGOTE; PROCEDURES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CARRIER STATE; HUMANS; INFECTION CONTROL; MUPIROCIN;

EID: 77954888193     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833ae214     Document Type: Review

References (53)

1. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002; 346:1871-1877.
2. von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphy-lococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344:11-16.
3. McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009; 29:263-280.
4. Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999; 180:896-899.
5. Mody L, Kauffman CA, McNeil SA, et al. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:1467-1474.
6. Fernandez C, Gaspar C, Torrellas A, et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995; 35:399-408.
7. Baker SE, Brecher SM, Robillard E, et al. Extranasal methicillin- resistant Staphylococcus aureus colonization at admission to an acute care Veterans Affairs hospital. Infect Control Hosp Epidemiol 31:42-46.
8. Mongkolrattanothai K, Mankin P, Raju V, Gray B. Surveillance for mupirocin resistance among methicillin-resistant Staphylococcus aureus clinical isolates. Infect Control Hosp Epidemiol 2008; 29:993-994.
9. Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2009): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 2002; 42:283-290.
10. Simor AE, Stuart TL, Louie L, et al. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007; 51:3880-3886.
11. Netto dos Santos KR, de Souza Fonseca L, Gontijo Filho PP. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol 1996; 17:813-816.
12. Patel Jean B, Gorwitz Rachel J, Jernigan John A. Antimicrobial resistance: mupirocin resistance. Clin Infect Dis 2009; 49:935-941.
13. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17:811-813.
14. Vasquez JE, Walker ES, Franzus BW, et al. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans? Affairs hospital. Infect Control Hosp Epidemiol 2000; 21:459-464.
15. Babu T, Rekasius V, Parada JP, et al. Mupirocin resistance among methicillin-resistant Staphylococcus aureus-colonized patients at admission to a tertiary care medical center. J Clin Microbiol 2009; 47:2279-2280.
16. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999; 12:147-179.
17. Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008; 46:274-281.
18. Higgins CS, Murtough SM, Williamson E, et al. Resistance to antibiotics and biocides among nonfermenting Gram-negative bacteria. Clin Microbiol Infect 2001; 7:308-315.
19. Popovich Kyle J, Hota B, Hayes R, et al. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 2009; 30: 959-963.
20. Scannapieco FA, Yu J, Raghavendran K, et al. A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients. Crit Care 2009; 13:R117.
21. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10:505-520.
22. Segers P, Speekenbrink RGH, Ubbink DT, et al. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 2006; 296:2460-2466.
23. Kallen AJ, Wilson CT, Larson RJ. Perioperative intranasal mupirocin for the prevention of surgical-site infections: systematic review of the literature and meta-analysis. Infect Control Hosp Epidemiol 2005; 26:916-922.
24. Jog S, Cunningham R, Cooper S, et al. Impact of preoperative screening for meticillin-resistant Staphylococcus aureus by real-time polymerase chain reaction in patients undergoing cardiac surgery. J Hosp Infect 2008; 69:124-130.
25. Rao N, Cannella B, Crossett L, et al. A preoperative decolonization protocol for Staphylococcus aureus prevents orthopaedic infections. Clin Orthop Relat Res 2008; 466:1343-1348.
26. Hacek DM, Robb WJ, Paule SM, et al. Staphylococcus aureus nasal decolonization in joint replacement surgery reduces infection. Clin Orthop Relat Res 2008; 466:1349-1355.
27. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299:1149-1157.
28. Bode LGM, Kluytmans JAJW, Wertheim HFL, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362:9-17.
29. Garcia R. A review of the possible role of oral and dental colonization on the occurrence of healthcare-associated pneumonia: underappreciated risk and a call for interventions. Am J Infect Control 2005; 33:527-541.
30. Houston S, Hougland P, Anderson JJ, et al. Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. Am J Crit Care 2002; 11:567-570.
31. DeRiso AJ 2nd, Ladowski JS, Dillon TA, et al. Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest 1996; 109:1556-1561.
32. Panchabhai TS, Dangayach NS, Krishnan A, et al. Oropharyngeal cleansing with 0.2% chlorhexidine for prevention of nosocomial pneumonia in critically ill patients: an open-label randomized trial with 0.01% potassium permanganate as control. Chest 2009; 135:1150-1156.
33. Bellissimo-Rodrigues F, Bellissimo-Rodrigues Wanessa T, Viana Jaciara M, et al. Effectiveness of oral rinse with chlorhexidine in preventing nosocomial respiratory tract infections among intensive care unit patients. Infect Control Hosp Epidemiol 2009; 30:952-958.
34. Munro CL, Grap MJ, Jones DJ, et al. Chlorhexidine, toothbrushing, and preventing ventilator-associated pneumonia in critically ill adults. Am J Crit Care 2009; 18:428-437.
35. Tantipong H, Morkchareonpong C, Jaiyindee S, Thamlikitkul V. Randomized controlled trial and meta-analysis of oral decontamination with 2% chlorhex idine solution for the prevention of ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2008; 29:131-136.
36. Liberati A, D?Amico R, Pifferi S, et al. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2009:CD000022.
37. Agrafiotis M, Siempos II, Falagas ME. Frequency, prevention, outcome and treatment of ventilator-associated tracheobronchitis: systematic review and meta-analysis. Respir Med 2010; 104:325-336.
38. Pujol M, Pena C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-sus-ceptible strains. Am J Med 1996; 100:509-516.
39. MimozO, Villeminey S, RagotS, et al. Chlorhexidine-based antiseptic solution vs alcohol-based povidone-iodine for central venous catheter care. Arch Intern Med 2007; 167:2066-2072.
40. Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007; 167:2073-2079.
41. Edwards JR, Peterson KD, Mu Y, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control 2009; 37:783-805.
42. Silvestri L, van Saene HKF, Milanese M, etal. Selective decontamination of the digestive tract reduces bacterial bloodstream infection and mortality in critically ill patients: systematic review of randomized, controlled trials. J Hosp Infect 2007; 65:187-203.
43. de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009; 360:20-31.
44. de Smet AM, Hopmans TE, Minderhoud AL, et al. Decontamination of the digestive tract and oropharynx: hospital acquired infections after discharge from the intensive care unit. Intensive Care Med 2009; 35:1609-1613.
45. Silvestri L, van Saene HK, Weir I, Gullo A. Survival benefit of the full selective digestive decontamination regimen. J Crit Care 2009; 24:474 e7-474 e14.
46. Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 (Suppl 1):S31-S40.
47. Marschall J, Mermel LA, Classen D, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 (Suppl 1):S22-S30.
48. McCann M, Moore ZE. Interventions for preventing infectious complications in haemodialysis patients with central venous catheters. Cochrane Database Syst Rev 2010:CD006894.
49. Keshtgar MR, Khalili A, Coen PG, et al. Impact of rapid molecular screening for meticillin-resistant Staphylococcus aureus in surgical wards. Br J Surg 2008; 95:381-386.
50. Vos MC, Behrendt MD, Melles DC, etal. 5 years of experience implementing a methicillin resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect Control Hosp Epidemiol 2009; 30:977-984.
51. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409-418.
52. Robicsek A, Beaumont JL, Thomson RB Jr, et al. Topical therapy for methicillin-resistant Staphylococcus aureus colonization: impact on infection risk. Infect Control Hosp Epidemiol 2009; 30:623-632.
53. Wertheim HF, Vos MC, Ott A, etal. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 2004; 140:419-425.